Skip to main content
. Author manuscript; available in PMC: 2024 Feb 21.
Published in final edited form as: Am J Infect Control. 2022 Jul 28;51(1):70–77. doi: 10.1016/j.ajic.2022.04.003

Table 1.

Carbapenem-resistant Enterobacterales (CRE) crude incidence, by Emerging Infections Program site and epidemiological classification, 2012-2015, n = 1499

 EIP Site Crude incidence rates per 100,000 population (95% confidence cnterval)
2012
2013
2014
2015
Overall
CA HCA CA HCA CA HCA CA HCA CA HCA
 CO 0.12 (0.02, 0.34) 0.93 (0.60, 1.38) 0.04 (0.00, 0.21) 0.61 (0.35, 0.99) 0.33 (0.15, 0.63) 0.93 (0.60, 1.37) 0.16 (0.09, 0.28) 0.82 (0.63, 1.05)
 GA 0.21 (0.09, 0.41) 4.16 (3.54, 4.86) 0.13 (0.04, 0.30) 4.11 (3.50, 4.81) 0.20 (0.09, 0.40) 3.90 (3.30, 4.57) 0.13 (0.04, 0.29) 3.43 (2.88, 4.06) 0.17 (0.11, 0.24) 3.90 (3.59, 4.22)
 MD 0.05 (0.00, 0.29) 4.43 (3.54, 5.48) 0.52 (0.25, 0.95) 7.68 (6.49, 9.02) 0.31 (0.11, 0.68) 6.67 (5.57, 7.93) 0.29 (0.17, 0.47) 6.27 (5.64, 6.94)
 MN 0.29 (0.10, 0.68) 1.53 (1.00, 2.23) 0.35 (0.13, 0.76) 1.85 (1.27, 2.62) 0.23 (0.06, 0.59) 2.18 (1.54, 2.99) 0.40 (0.16, 0.82) 2.55 (1.86, 2.42) 0.32 (0.20, 0.48) 2.03 (1.71, 2.40)
 NM 0.00 (0.00, 0.44) 1.33 (0.61, 2.53) 2.66 (1.58, 4.21) 4.29 (2.87, 6.17) 1.48 (0.71, 2.72) 3.10 (1.92, 4.74) 1.38 (0.92, 2.00) 2.91 (2.22, 3.76)
 NY 0.93 (0.38, 1.92) 2.53 (1.53, 3.96) 1.33 (0.64, 2.45) 4.80 (3.36, 6.65) 0.80 (0.29, 1.74) 1.73 (0.92, 2.97) 1.02 (0.65, 1.53) 3.02 (2.35, 3.83)
 OR 0.12 (0.01, 0.43) 0.24 (0.06, 0.61) 0.23 (0.06, 0.60) 0.47 (0.20, 0.92) 0.00 (0.00, 0.17) 0.52 (0.24, 0.98) 0.28 (0.09, 0.66) 0.17 (0.04, 0.50) 0.16 (0.08, 0.29) 0.35 (0.22, 0.52)
 TN 0.31 (0.10, 0.72) 0.68 (0.34, 1.22) 0.24 (0.07, 0.62) 0.73 (0.37, 1.27) 0.27 (0.13, 0.52) 0.70 (0.45, 1.05)
0.21 (0.12, 0.34) 2.62 (2.26, 3.02) 0.20 (0.13, 0.29) 2.54 (2.28, 2.83) 0.37 (0.28, 0.48) 2.93 (2.66, 3.22) 0.34 (0.26, 0.45) 2.53 (2.28, 2.79) 0.29 (0.25, 0.35) 2.66 (2.52, 2.81)
Overall

CA, community-associated; HCA, health care-associated.